BioCentury | Jan 12, 2019
Finance

We all fall down

...peripheral T-cell lymphoma (PTCL) under the Real-Time Oncology Review (RTOR) program Servier FDA approves Asparlas calaspargase pegol-mknl...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Jan 4, 2019
Clinical News

FDA approves Servier's ALL therapy acquired in Shire deal

...FDA approved Asparlas calaspargase pegol-mknl (formerly SHP663) from Servier (Suresnes, France) to treat acute lymphoblastic leukemia in...
...Oncaspar for $2.4B" ). Servier, Suresnes, France Product: Asparlas (calaspargase pegol, EZN-2285, SHP663) Business: Cancer Sandi Wong calaspargase pegol (EZN-2285...
BioCentury | Dec 31, 2018
Politics & Policy

FDA closes 2018 with record NME approvals

...four have been added to the list: Motegrity prucalopride from Shire plc (LSE:SHP; NASDAQ:SHPG); Asparlas calaspargase pegol-mknl...
BioCentury | Dec 21, 2018
Company News

FDA approves Servier's ALL therapy acquired in Shire deal

...FDA approved Asparlas calaspargase pegol-mknl (formerly SHP663) from Servier (Suresnes, France) to treat acute lymphoblastic leukemia in...
...for $2.4 billion (see "Servier to Gain Shire's Cancer Business, Oncaspar for $2.4B" ). Sandi Wong calaspargase pegol (EZN-2285...
BioCentury | Dec 5, 2018
Politics & Policy

FDA breaks NME approval record in 2018

...be categorized as NMEs have PDUFA dates remaining in December: solriamfetol (JZP-110), prucalopride (SHP-555) and calaspargase pegol...
...plc (LSE:SHP; NASDAQ:SHPG) is developing the other two: prucalopride to treat chronic idiopathic constipation and calaspargase pegol...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...Lusutrombopag Thrombocytopenia associated with chronic liver disease PDUFA date 8/26/18 Shire plc (NASDAQ:SHPG; LSE:SHP) Calaspargase pegol (EZN-2285...
BioCentury | Apr 20, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

...rights outside of the U.S. and Taiwan to pancreatic cancer drug Onivyde irinotecan, plus Shire's calaspargase pegol...
...March 9) . Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Servier, Suresnes, France Business: Cancer Jennie Walters calaspargase pegol (EZN-2285) Oncaspar...
BioCentury | Apr 16, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

...rights outside of the U.S. and Taiwan to pancreatic cancer drug Onivyde irinotecan, plus Shire's calaspargase pegol...
...47.50p to 3,559p in London and gained $0.22 to $152.41 on NASDAQ on Monday. Jennie Walters calaspargase pegol (EZN-2285) Oncaspar...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

...III testing, while bluebird bio Inc.’s Lenti-D is in Phase II/III. In cancer, Shire has calaspargase pegol...
Items per page:
1 - 10 of 15